TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

NCT01605734 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

PHENYTOIN/SORAFENIB [VA Drug Interaction]
Carcinoma, Hepatocellular

Interventions

PROCEDURE: TACE
DRUG: sorafenib combined with TACE

Sponsor

Shandong Cancer Hospital and Institute